Skip to main content
Top

05-05-2024 | Rheumatoid Arthritis | ORIGINAL ARTICLE

Multidimensional biomarker approach integrating tumor markers, inflammatory indicators, and disease activity indicators may improve prediction of rheumatoid arthritis-associated interstitial lung disease

Authors: Jin Wan, Zhibo Yu, Xiaoyu Cao, Xuejian Zhao, Wei Zhou, Yi Zheng

Published in: Clinical Rheumatology

Login to get access

Abstract

Introduction

Rheumatoid arthritis (RA) often leads to interstitial lung disease (ILD), significantly affecting patient outcomes. This study explored the diagnostic accuracy of a multi-biomarker approach to offer a more efficient and accessible diagnostic strategy for RA-associated ILD (RA-ILD).

Methods

Patients diagnosed with RA, with or without ILD, at Beijing Tiantan Hospital from October 2019 to October 2023 were analyzed. A total of 125 RA patients were included, with 76 diagnosed with RA-ILD. The study focused on three categories of indicators: tumor markers, inflammatory indicators, and disease activity measures. The heatmap correlation analysis was employed to analyze the correlation among these indicators. Logistic regression was used to determine odds ratios (OR) for indicators linked to RA-ILD risk. Receiver-operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic potential of these indicators for RA-ILD.

Results

The results of logistic regression analysis showed that tumor markers (carbohydrate antigen 19–9 (CA19-9), carbohydrate antigen 125 (CA125), and cytokeratin 19 fragment (CYFRA21-1)), as well as inflammatory indicators (neutrophil, neutrophil-to-lymphocyte ratio (NLR), platelet, C-reactive protein (CRP)) and disease activity measures (disease activity score-28-CRP (DAS28-CRP), rheumatoid factor (RF), and anti-cyclic peptide containing citrulline (anti-CCP)), were significantly associated with RA-ILD. The correlation coefficients among these indicators were relatively low. Notably, the combination indicator 4, which integrated the aforementioned three categories of biomarkers, demonstrated improved diagnostic accuracy with an AUC of 0.857.

Conclusion

The study demonstrated that combining tumor markers, inflammatory indicators, and disease activity measures significantly enhanced the prediction of RA-ILD.
Key Points
Multidimensional strategy: Integrated tumor markers, inflammatory indicators, and disease activity measures to enhance early detection of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Diagnostic accuracy: Employed heatmap correlation and logistic regression, identifying significant associations and improving diagnostic accuracy with a multidimensional biomarker combination.
Superior performance: The combined multidimensional biomarker strategy demonstrated higher diagnostic precision compared to individual or dual-category indicators.
Clinical relevance: Offers a promising, accessible approach for early detection of RA-ILD in clinical settings, potentially improving patient outcomes.
Literature
1.
2.
go back to reference Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J et al (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49:1483–1489PubMedCrossRef Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J et al (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49:1483–1489PubMedCrossRef
3.
go back to reference Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J et al (2011) Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372–378PubMedPubMedCentralCrossRef Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J et al (2011) Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372–378PubMedPubMedCentralCrossRef
4.
go back to reference Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583–1591PubMedPubMedCentralCrossRef Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583–1591PubMedPubMedCentralCrossRef
5.
go back to reference Yamakawa H, Ogura T, Kameda H et al (2021) Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)[J]. J Clin Med 10(17):3806 Yamakawa H, Ogura T, Kameda H et al (2021) Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)[J]. J Clin Med 10(17):3806
6.
go back to reference Fotoh DS, Helal A, Rizk MS, Esaily HA (2021) Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 40:2689–2697PubMedCrossRef Fotoh DS, Helal A, Rizk MS, Esaily HA (2021) Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 40:2689–2697PubMedCrossRef
7.
go back to reference Florescu A, Gherghina FL, Musetescu AE et al (2022) Novel biomarkers, diagnostic and therapeutic approach in rheumatoid arthritis interstitial lung disease-a narrative review[J]. Biomedicines 10(6):1367 Florescu A, Gherghina FL, Musetescu AE et al (2022) Novel biomarkers, diagnostic and therapeutic approach in rheumatoid arthritis interstitial lung disease-a narrative review[J]. Biomedicines 10(6):1367
8.
go back to reference Mori S, Koga Y, Sugimoto M (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106:1591–1599PubMedCrossRef Mori S, Koga Y, Sugimoto M (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106:1591–1599PubMedCrossRef
9.
go back to reference Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M et al (2019) Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. Scand J Rheumatol 48:87–94PubMedCrossRef Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M et al (2019) Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. Scand J Rheumatol 48:87–94PubMedCrossRef
10.
go back to reference Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC et al (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 191:1403–1412PubMedPubMedCentralCrossRef Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC et al (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 191:1403–1412PubMedPubMedCentralCrossRef
11.
go back to reference Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y et al (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67:28–38PubMedPubMedCentralCrossRef Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y et al (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67:28–38PubMedPubMedCentralCrossRef
12.
go back to reference Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV et al (2013) Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 65:869–879PubMedCrossRef Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV et al (2013) Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 65:869–879PubMedCrossRef
13.
go back to reference Restrepo JF, del Rincon I, Battafarano DF, Haas RW, Doria M, Escalante A (2015) Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 34:1529–1536PubMedCrossRef Restrepo JF, del Rincon I, Battafarano DF, Haas RW, Doria M, Escalante A (2015) Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 34:1529–1536PubMedCrossRef
14.
go back to reference Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford) 53:1676–1682PubMedCrossRef Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford) 53:1676–1682PubMedCrossRef
15.
go back to reference Habib HM, Eisa AA, Arafat WR, Marie MA (2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30:217–221PubMedCrossRef Habib HM, Eisa AA, Arafat WR, Marie MA (2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30:217–221PubMedCrossRef
16.
go back to reference Zheng M, Lou A, Zhang H, Zhu S, Yang M, Lai W (2021) Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. Rheumatol Ther 8:517–527PubMedPubMedCentralCrossRef Zheng M, Lou A, Zhang H, Zhu S, Yang M, Lai W (2021) Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. Rheumatol Ther 8:517–527PubMedPubMedCentralCrossRef
17.
go back to reference Mena-Vazquez N, Godoy-Navarrete FJ, Lisbona-Montanez JM et al (2023) Inflammatory biomarkers in the diagnosis and prognosis of rheumatoid arthritis-associated interstitial lung disease[J]. Int J Mol Sci 24(7):6800 Mena-Vazquez N, Godoy-Navarrete FJ, Lisbona-Montanez JM et al (2023) Inflammatory biomarkers in the diagnosis and prognosis of rheumatoid arthritis-associated interstitial lung disease[J]. Int J Mol Sci 24(7):6800
18.
go back to reference Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I et al (2023) Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 11:87–96PubMedCrossRef Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I et al (2023) Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 11:87–96PubMedCrossRef
19.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581PubMedCrossRef
20.
go back to reference Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM et al (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol 71:1472–1482PubMedPubMedCentralCrossRef Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM et al (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol 71:1472–1482PubMedPubMedCentralCrossRef
21.
go back to reference Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB et al (2019) Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc 94:309–325PubMedCrossRef Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB et al (2019) Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc 94:309–325PubMedCrossRef
23.
go back to reference Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A et al (2019) Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 46:360–369PubMedCrossRef Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A et al (2019) Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 46:360–369PubMedCrossRef
24.
go back to reference Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706PubMedCrossRef Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706PubMedCrossRef
25.
go back to reference Manfredi A, Cassone G, Luppi F, Atienza-Mateo B, Cavazza A, Sverzellati N et al (2021) Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol 17:485–497PubMedCrossRef Manfredi A, Cassone G, Luppi F, Atienza-Mateo B, Cavazza A, Sverzellati N et al (2021) Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol 17:485–497PubMedCrossRef
26.
go back to reference Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627PubMedPubMedCentralCrossRef Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56:622–627PubMedPubMedCentralCrossRef
27.
go back to reference Paschalaki KE, Jacob J, Wells AU (2016) Monitoring of lung involvement in rheumatologic disease. Respiration 91:89–98PubMedCrossRef Paschalaki KE, Jacob J, Wells AU (2016) Monitoring of lung involvement in rheumatologic disease. Respiration 91:89–98PubMedCrossRef
28.
go back to reference Correia CS, Briones MR, Guo R, Ostrowski RA (2019) Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 38:1201–1206PubMedPubMedCentralCrossRef Correia CS, Briones MR, Guo R, Ostrowski RA (2019) Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 38:1201–1206PubMedPubMedCentralCrossRef
29.
go back to reference Sebastiani M, Manfredi A, Cerri S, Della Casa G, Luppi F, Ferri C (2016) Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease. Clin Exp Rheumatol 34:564–565PubMed Sebastiani M, Manfredi A, Cerri S, Della Casa G, Luppi F, Ferri C (2016) Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease. Clin Exp Rheumatol 34:564–565PubMed
30.
go back to reference Zhang Y, Li H, Wu N, Dong X, Zheng Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 36:817–823PubMedCrossRef Zhang Y, Li H, Wu N, Dong X, Zheng Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 36:817–823PubMedCrossRef
31.
go back to reference Wang J, Devenport J, Low JM, Yu D, Hitraya E (2016) Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:882–885PubMedCrossRef Wang J, Devenport J, Low JM, Yu D, Hitraya E (2016) Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:882–885PubMedCrossRef
32.
go back to reference Wu X, Xu L, Cheng Q, Nie L, Zhang S, Du Y et al (2020) Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study. Respir Med 166:105948PubMedCrossRef Wu X, Xu L, Cheng Q, Nie L, Zhang S, Du Y et al (2020) Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study. Respir Med 166:105948PubMedCrossRef
33.
go back to reference Liao KP, Sparks JA, Hejblum BP, Kuo IH, Cui J, Lahey LJ et al (2017) Phenome-wide association study of autoantibodies to citrullinated and noncitrullinated epitopes in rheumatoid arthritis. Arthritis Rheumatol 69:742–749PubMedPubMedCentralCrossRef Liao KP, Sparks JA, Hejblum BP, Kuo IH, Cui J, Lahey LJ et al (2017) Phenome-wide association study of autoantibodies to citrullinated and noncitrullinated epitopes in rheumatoid arthritis. Arthritis Rheumatol 69:742–749PubMedPubMedCentralCrossRef
34.
go back to reference Avouac J, Cauvet A, Steelandt A, Shirai Y, Elhai M, Kuwana M et al (2020) Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One 15:e0232978PubMedPubMedCentralCrossRef Avouac J, Cauvet A, Steelandt A, Shirai Y, Elhai M, Kuwana M et al (2020) Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS One 15:e0232978PubMedPubMedCentralCrossRef
35.
go back to reference Molina R, Marrades RM, Auge JM, Escudero JM, Vinolas N, Reguart N et al (2016) Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 193:427–437PubMedCrossRef Molina R, Marrades RM, Auge JM, Escudero JM, Vinolas N, Reguart N et al (2016) Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 193:427–437PubMedCrossRef
36.
go back to reference Schneider J (2010) Early detection of lung cancers - comparison of computed tomography, cytology and fuzzy-based tumor markers panels. Cancer Biomark 6:149–162PubMedCrossRef Schneider J (2010) Early detection of lung cancers - comparison of computed tomography, cytology and fuzzy-based tumor markers panels. Cancer Biomark 6:149–162PubMedCrossRef
37.
go back to reference Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA et al (2017) An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 5:946–955PubMedCrossRef Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA et al (2017) An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 5:946–955PubMedCrossRef
38.
go back to reference Yamamoto S, Kobayashi S, Tanaka M, Akimoto T, Takasaki Y (1996) Serum CA 19–9 levels in rheumatic diseases with interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 19:128–135PubMedCrossRef Yamamoto S, Kobayashi S, Tanaka M, Akimoto T, Takasaki Y (1996) Serum CA 19–9 levels in rheumatic diseases with interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 19:128–135PubMedCrossRef
40.
go back to reference Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F et al (2004) Elevation of cytokeratin 19 fragment (CYFRA 21–1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med 98:294–300PubMedCrossRef Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F et al (2004) Elevation of cytokeratin 19 fragment (CYFRA 21–1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med 98:294–300PubMedCrossRef
42.
go back to reference Juge PA, Borie R, Kannengiesser C et al (2017) Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis[J]. Eur Respir J 49(5):1602314 Juge PA, Borie R, Kannengiesser C et al (2017) Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis[J]. Eur Respir J 49(5):1602314
43.
go back to reference Manfredi A, Luppi F, Cassone G, Vacchi C, Salvarani C, Sebastiani M (2020) Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. Expert Rev Clin Immunol 16:751–770PubMedPubMedCentralCrossRef Manfredi A, Luppi F, Cassone G, Vacchi C, Salvarani C, Sebastiani M (2020) Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. Expert Rev Clin Immunol 16:751–770PubMedPubMedCentralCrossRef
44.
go back to reference Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V (2018) The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 70:1544–1554PubMedCrossRef Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V (2018) The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 70:1544–1554PubMedCrossRef
45.
go back to reference Akiyama M, Kaneko Y (2022) Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 21:103056PubMedCrossRef Akiyama M, Kaneko Y (2022) Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev 21:103056PubMedCrossRef
Metadata
Title
Multidimensional biomarker approach integrating tumor markers, inflammatory indicators, and disease activity indicators may improve prediction of rheumatoid arthritis-associated interstitial lung disease
Authors
Jin Wan
Zhibo Yu
Xiaoyu Cao
Xuejian Zhao
Wei Zhou
Yi Zheng
Publication date
05-05-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06984-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.